Price
Target price
€1.16
€1.16
-
-
-
€1.60
19.07.24 / Frankfurt
WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cerenis Therapeutics Holding S.A. Stock
The community is currently still undecided about Cerenis Therapeutics Holding S.A. with 1 Buy predictions and 0 Sell predictions.
However, we have a potential of -13.79% for Cerenis Therapeutics Holding S.A. as the target price of 1 € is below the current price of 1.16 €.
For the coming years our community has positive and negative things to say abot the Cerenis Therapeutics Holding S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | - | -0.344% | -5.074% | 0.520% | -5.844% | 29.609% | 317.266% |
| Sensorion SA | 0.310% | -3.284% | 1.567% | 114.570% | 62.000% | -62.326% | - |
| Genoway S.A. Inh. | 0.720% | 2.934% | 5.250% | 12.869% | -4.535% | 9.493% | 165.615% |
| Hybrigenics S.A. | - | -10.714% | 72.414% | -89.648% | -73.545% | -96.324% | -93.750% |
News
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
Access here the full press release
ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies